Odyssean LLC Has $685,000 Position in Supernus Pharmaceuticals, Inc. $SUPN

Odyssean LLC cut its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 46.6% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,738 shares of the specialty pharmaceutical company’s stock after selling 12,852 shares during the period. Odyssean LLC’s holdings in Supernus Pharmaceuticals were worth $685,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. lifted its position in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 660 shares in the last quarter. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $51,000. Hantz Financial Services Inc. grew its holdings in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 458 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals in the second quarter worth $55,000. Finally, Osaic Holdings Inc. increased its stake in shares of Supernus Pharmaceuticals by 211.5% in the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after acquiring an additional 1,328 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Stock Down 1.0%

Shares of SUPN opened at $43.53 on Friday. The company’s fifty day moving average is $46.69 and its 200-day moving average is $48.41. Supernus Pharmaceuticals, Inc. has a 12 month low of $42.45 and a 12 month high of $59.68. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of -22.67, a price-to-earnings-growth ratio of 0.81 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). The business had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm’s revenue for the quarter was up 32.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.40 EPS. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.